✦ LIBER ✦

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)

✍ Scribed by Hyeon-Seok Eom; Yeo-Kyeoung Kim; Joo-Seop Chung; Kihyun Kim; Hyo Jung Kim; Ho Young Kim; Jong-Youl Jin; Young-Rok Do; Suk-Joong Oh; Cheolwon Suh; Chu-Myong Seong; Chul Soo Kim; Dong Soon Lee; Jae Hoon Lee

Publisher: Springer
Year: 2009
Tongue: English
Weight: 153 KB
Volume: 89
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-009-0871-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB